Ben Tre Pharmaceutical JSC (HOSE: DBT)
Vietnam
· Delayed Price · Currency is VND 12,850
-250 (-1.91%)
At close: Sep 27, 2024
DBT Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | 2014 - 2010 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '20 Jun 30, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | 2014 - 2010 |
| Revenue | 828,640 | 800,500 | 809,914 | 800,114 | 580,517 | 552,116 | Upgrade
|
| Revenue Growth (YoY) | 1.91% | -1.16% | 1.22% | 37.83% | 5.14% | 5.52% | Upgrade
|
| Cost of Revenue | 628,827 | 615,255 | 628,852 | 614,223 | 439,914 | 425,635 | Upgrade
|
| Gross Profit | 199,813 | 185,245 | 181,063 | 185,890 | 140,603 | 126,481 | Upgrade
|
| Selling, General & Admin | 170,173 | 155,629 | 153,771 | 154,783 | 107,815 | 122,730 | Upgrade
|
| Operating Expenses | 170,173 | 155,629 | 153,771 | 154,783 | 107,815 | 122,730 | Upgrade
|
| Operating Income | 29,640 | 29,616 | 27,292 | 31,107 | 32,788 | 3,750 | Upgrade
|
| Interest Expense | -18,484 | -15,184 | -13,210 | -11,178 | -9,810 | -9,194 | Upgrade
|
| Interest & Investment Income | 10,916 | 8,982 | 4,607 | 6,155 | 3,830 | 34,555 | Upgrade
|
| Earnings From Equity Investments | 4,481 | 5,829 | 5,584 | 6,557 | 3,981 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 273.32 | 592.9 | 2,352 | 2,180 | -250.64 | 500.49 | Upgrade
|
| EBT Excluding Unusual Items | 26,825 | 29,836 | 26,625 | 34,822 | 30,539 | 29,612 | Upgrade
|
| Pretax Income | 26,825 | 29,836 | 26,625 | 34,822 | 30,539 | 29,612 | Upgrade
|
| Income Tax Expense | 5,926 | 5,715 | 5,172 | 6,575 | 6,522 | 7,409 | Upgrade
|
| Earnings From Continuing Operations | 20,899 | 24,121 | 21,453 | 28,246 | 24,017 | 22,203 | Upgrade
|
| Minority Interest in Earnings | -4,007 | -2,725 | -1,260 | 490.31 | -355.08 | - | Upgrade
|
| Net Income | 16,892 | 21,396 | 20,193 | 28,737 | 23,662 | 22,203 | Upgrade
|
| Net Income to Common | 16,892 | 21,396 | 20,193 | 28,737 | 23,662 | 22,203 | Upgrade
|
| Net Income Growth | -23.19% | 5.95% | -29.73% | 21.45% | 6.57% | 95.32% | Upgrade
|
| Shares Outstanding (Basic) | 18 | - | - | 16 | 12 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | - | - | 16 | 12 | 11 | Upgrade
|
| Shares Change (YoY) | - | - | - | 30.49% | 10.76% | -4.10% | Upgrade
|
| EPS (Basic) | 948.29 | - | - | 1785.52 | 1918.43 | 1993.79 | Upgrade
|
| EPS (Diluted) | 948.29 | - | - | 1785.52 | 1918.43 | 1993.79 | Upgrade
|
| EPS Growth | - | - | - | -6.93% | -3.78% | 103.68% | Upgrade
|
| Free Cash Flow | -80,937 | -80,940 | -21,328 | 42,056 | 28,210 | -61,403 | Upgrade
|
| Free Cash Flow Per Share | -4543.59 | - | - | 2613.12 | 2287.19 | -5513.80 | Upgrade
|
| Gross Margin | 24.11% | 23.14% | 22.36% | 23.23% | 24.22% | 22.91% | Upgrade
|
| Operating Margin | 3.58% | 3.70% | 3.37% | 3.89% | 5.65% | 0.68% | Upgrade
|
| Profit Margin | 2.04% | 2.67% | 2.49% | 3.59% | 4.08% | 4.02% | Upgrade
|
| Free Cash Flow Margin | -9.77% | -10.11% | -2.63% | 5.26% | 4.86% | -11.12% | Upgrade
|
| EBITDA | 42,660 | 42,952 | 40,299 | 42,885 | 37,329 | 7,609 | Upgrade
|
| EBITDA Margin | 5.15% | 5.37% | 4.98% | 5.36% | 6.43% | 1.38% | Upgrade
|
| D&A For EBITDA | 13,020 | 13,336 | 13,007 | 11,778 | 4,541 | 3,859 | Upgrade
|
| EBIT | 29,640 | 29,616 | 27,292 | 31,107 | 32,788 | 3,750 | Upgrade
|
| EBIT Margin | 3.58% | 3.70% | 3.37% | 3.89% | 5.65% | 0.68% | Upgrade
|
| Effective Tax Rate | 22.09% | 19.15% | 19.43% | 18.88% | 21.36% | 25.02% | Upgrade
|
| Revenue as Reported | 828,640 | 800,500 | 809,914 | 800,114 | 580,517 | 552,116 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.